Skip to main content
. 2021 Sep 27;27(21):5857–5868. doi: 10.1158/1078-0432.CCR-19-2384

Figure 5.

Figure 5. Length distributions of human-mapping cfDNA and HPV-mapping ctDNA fragments for 13 patients with cervix cancer. A, Sequenced fragment insert sizes merged from HPV-seq positive patients analyzed at end-of-treatment or posttreatment (N = 13). Samples (N = 3) from patients with recurrence (B) and samples (N = 10) from patients without recurrence (C) display similar ctDNA fragment-size distributions. Samples from tumors harboring HPV-16 (N = 9; D), HPV-33 (N = 2; E), and HPV-52 (N = 2; F) are shown.

Length distributions of human-mapping cfDNA and HPV-mapping ctDNA fragments for 13 patients with cervix cancer. A, Sequenced fragment insert sizes merged from HPV-seq positive patients analyzed at end-of-treatment or posttreatment (N = 13). Samples (N = 3) from patients with recurrence (B) and samples (N = 10) from patients without recurrence (C) display similar ctDNA fragment-size distributions. Samples from tumors harboring HPV-16 (N = 9; D), HPV-33 (N = 2; E), and HPV-52 (N = 2; F) are shown.